Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cyclophosphamide Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.96 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophosphamide Anhydrous SCHEMBL5436000 | 1.00 | KDM4E (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL7304 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4346 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL20542636 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL1285823 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL28088100 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5328735 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL14192809 | 0.98 | NPSR1 (1.00) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4994883 | 0.96 | NPSR1 (0.96) | KDM4EALOX15MAPK1NPSR1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5802618 | 0.96 | NPSR1 (0.96) | KDM4EALOX15MAPK1NPSR1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2748 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121570423-A | Multi-flexbile ratio Star and cyclophosphates amide liposome compound injection | 山西普德药业有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12453737-B2 | Method for hydrating lyophilized cyclophosphamide composition and product thereof | SINOTHERAPEUTICS INC. (CN) | 2025-10-28 | — | — | US | claimed |
| US-20250312363-A1 | METHOD FOR HYDRATING LYOPHILIZED CYCLOPHOSPHAMIDE COMPOSITION AND PRODUCT THEREOF | SINOTHERAPEUTICS INC (CN) | 2025-10-09 | — | — | US | claimed |
| EP-4622649-A1 | NOVEL SOLUTION FORMULATION OF CYCLOPHOSPHAMIDE | Navinta, LLC (US) | 2025-10-01 | — | — | EP | claimed |
| CN-110998328-B | Diagnosis and treatment of cancer | 拉布诊断公司 | 2025-05-02 | — | — | CN | claimed |
| EP-4398874-A1 | INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Xeris Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-12038436-B2 | Diagnosis of autoimmune disease | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-07-16 | — | — | US | claimed |
| US-20240180935-A1 | SOLUTION FORMULATION OF CYCLOPHOSPHAMIDE | NAVINTA LLC (US) | 2024-06-06 | — | — | US | claimed |
| WO-2024112860-A1 | NOVEL SOLUTION FORMULATION OF CYCLOPHOSPHAMIDE | NAVINTA, LLC (US) | 2024-05-30 | — | — | WO | claimed |
| CN-118103030-A | Injectable high concentration pharmaceutical formulations and methods of making and using the same | XERIS药物公司 | 2024-05-28 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5418223-A | Method for lyophilization of cyclophosphamide and product | ERBAMONT, INC. (US) | 1995-05-23 | — | — | US | claimed |
| US-5413995-A | Mannitol as excipient | MEAD JOHNSON & COMPANY (US) | 1995-05-09 | — | — | US | claimed |
| US-5336669-A | Mixture with hydrate which has been melted, precipitated, refrozen and redried, crystal structure, water solubility | ERBAMONT, INC. (US) | 1994-08-09 | — | — | US | claimed |
| US-5066647-A | Freeze dried, quick dissolving, improved shelf life | ERBAMONT, INC. (US) | 1991-11-19 | — | — | US | claimed |